Siegfried Holding AG (VTX:SFZN) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Feb 21
Have your own idea? Try our Stock Screener
Swiss (SMI) Clinical Research and Equipment Industry Analysis
UpdatedFeb 21, 2025
DataAggregated Company Financials
Companies7
- 7D-2.3%
- 3M5.8%
- 1Y13.7%
- YTDn/a
Over the last 7 days, the Clinical Research and Equipment industry has dropped 2.3%, driven by a pullback from Lonza Group of 2.3%. In the past year, the industry has gained 14%. Looking forward, earnings are forecast to grow by 20% annually.
Industry Valuation and Performance
Has the Swiss Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 22 Feb 2025 | CHF 56.1b | CHF 10.1b | CHF 1.0b | 32.6x | 54.1x | 5.6x |
| Mon, 20 Jan 2025 | CHF 54.0b | CHF 10.2b | CHF 943.4m | 34.9x | 57.3x | 5.3x |
| Wed, 18 Dec 2024 | CHF 53.5b | CHF 10.2b | CHF 943.4m | 37.5x | 56.7x | 5.2x |
| Fri, 15 Nov 2024 | CHF 56.3b | CHF 10.2b | CHF 943.5m | 43x | 59.7x | 5.5x |
| Sun, 13 Oct 2024 | CHF 54.1b | CHF 10.2b | CHF 943.5m | 41.4x | 57.4x | 5.3x |
| Tue, 10 Sep 2024 | CHF 56.4b | CHF 10.2b | CHF 937.1m | 44.2x | 60.2x | 5.5x |
| Thu, 08 Aug 2024 | CHF 57.7b | CHF 10.2b | CHF 924.1m | 44.7x | 62.4x | 5.6x |
| Sat, 06 Jul 2024 | CHF 54.3b | CHF 10.3b | CHF 1.0b | 46.3x | 54.2x | 5.3x |
| Mon, 03 Jun 2024 | CHF 52.2b | CHF 10.3b | CHF 1.0b | 43.9x | 52.1x | 5.1x |
| Wed, 01 May 2024 | CHF 53.8b | CHF 10.3b | CHF 1.0b | 43.6x | 53.7x | 5.2x |
| Fri, 29 Mar 2024 | CHF 58.5b | CHF 10.3b | CHF 1.0b | 47x | 58.3x | 5.7x |
| Sun, 25 Feb 2024 | CHF 50.6b | CHF 10.2b | CHF 982.3m | 47.1x | 51.5x | 5x |
| Tue, 23 Jan 2024 | CHF 42.3b | CHF 9.8b | CHF 1.5b | 31.3x | 28.3x | 4.3x |
| Thu, 21 Dec 2023 | CHF 41.1b | CHF 9.8b | CHF 1.5b | 32.2x | 27.5x | 4.2x |
| Sat, 18 Nov 2023 | CHF 41.5b | CHF 9.8b | CHF 1.5b | 29.5x | 27.8x | 4.2x |
| Mon, 16 Oct 2023 | CHF 45.6b | CHF 9.8b | CHF 1.5b | 30.4x | 30.5x | 4.7x |
| Wed, 13 Sep 2023 | CHF 51.7b | CHF 9.8b | CHF 1.5b | 35x | 34.7x | 5.3x |
| Fri, 11 Aug 2023 | CHF 53.6b | CHF 9.8b | CHF 1.5b | 35.9x | 34.6x | 5.5x |
| Sun, 09 Jul 2023 | CHF 54.6b | CHF 9.7b | CHF 1.6b | 35.7x | 33.4x | 5.6x |
| Tue, 06 Jun 2023 | CHF 60.1b | CHF 9.7b | CHF 1.6b | 37.1x | 36.8x | 6.2x |
| Thu, 04 May 2023 | CHF 61.2b | CHF 9.7b | CHF 1.6b | 41.3x | 37.4x | 6.3x |
| Sat, 01 Apr 2023 | CHF 58.1b | CHF 9.7b | CHF 1.7b | 42x | 34.8x | 6x |
| Mon, 27 Feb 2023 | CHF 58.9b | CHF 9.6b | CHF 1.7b | 34.6x | 35.4x | 6.2x |
| Wed, 25 Jan 2023 | CHF 52.6b | CHF 9.2b | CHF 1.3b | 39.6x | 39.6x | 5.7x |
| Fri, 23 Dec 2022 | CHF 49.5b | CHF 9.2b | CHF 1.3b | 36.7x | 37.3x | 5.4x |
| Sun, 20 Nov 2022 | CHF 53.3b | CHF 9.2b | CHF 1.3b | 40.4x | 40.1x | 5.8x |
| Tue, 18 Oct 2022 | CHF 51.3b | CHF 9.2b | CHF 1.3b | 40.4x | 38.6x | 5.6x |
| Thu, 15 Sep 2022 | CHF 51.6b | CHF 9.2b | CHF 1.3b | 40.8x | 39.9x | 5.6x |
| Sat, 13 Aug 2022 | CHF 57.7b | CHF 8.9b | CHF 1.3b | 36.1x | 44x | 6.5x |
| Mon, 11 Jul 2022 | CHF 58.1b | CHF 8.5b | CHF 1.1b | 45.1x | 53.9x | 6.9x |
| Wed, 08 Jun 2022 | CHF 58.5b | CHF 8.5b | CHF 1.1b | 48.4x | 54.2x | 6.9x |
| Fri, 06 May 2022 | CHF 56.2b | CHF 8.5b | CHF 1.1b | 32.3x | 52x | 6.6x |
| Sun, 03 Apr 2022 | CHF 69.6b | CHF 8.3b | CHF 1.1b | 51.3x | 64.5x | 8.4x |
| Tue, 01 Mar 2022 | CHF 67.8b | CHF 8.0b | CHF 1.1b | 54.1x | 63.5x | 8.5x |
Price to Earnings Ratio
63.5x
Current Industry PE
- Investors are optimistic on the Swiss Life Sciences Tools and Services industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 54.1x which is higher than its 3-year average PE of 45.5x.
- The industry is trading close to its 3-year average PS ratio of 5.7x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have remained mostly flat over the last three years.
- Meanwhile revenues for these companies have grown 8.1% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased and as a result, profits have held steady.
Industry Comparison
How does Swiss Clinical Research and Equipment compare with similar industries?
| CH Market | -0.93% | |
| Healthcare | -1.21% | |
| Life Sciences | -2.34% | |
| Clinical Research and Equipment | -2.34% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| BANB Bachem Holding | CHF 58.95 | 4.0% +CHF 168.7m | -13.5% | PE38.9x | |
| SKAN SKAN Group | CHF 77.90 | 2.2% +CHF 38.2m | -4.9% | PE54.3x | |
| PPGN PolyPeptide Group | CHF 22.95 | 4.6% +CHF 33.0m | 40.5% | PS2.5x |
